US Stem Cell Training

NEJM paper links 3 blinded patients to publicly-traded stem cell clinic

stem-cells-eyes

Do 3 blinded stem cell clinic patients with major or complete vision loss constitute a significant adverse outcome? I would say so and a new paper details how this happened apparently at a particular publically-traded South Florida stem cell clinic business. You can see the damaged retinas of one such patient below in an image from a …

NEJM paper links 3 blinded patients to publicly-traded stem cell clinic Read More »

Bioheart on the edge in 2015?

Bioheart-logo

Stem cell biotech company Bioheart ($BHRT) has had a rough 2015 so far. Could this year be a decisive, negative tipping point for the company? It has a number of clinical trials going, but from my view things seem increasingly uncertain. An oddity amongst stem cell biotechs, Bioheart and its leadership have at times seemed to toy …

Bioheart on the edge in 2015? Read More »

Interview with Bioheart CSO, Kristin Comella including on FDA

Kristin-Comella1

I invited the Chief Scientific Officer (CSO) of Bioheart, Kristin Comella, to do an interview after hearing some buzz that this could be a critical time for the company and that it might have been recently visited by the FDA. Note that Comella not just Bioheart CSO, but also the primary instructor for physician training in stem …

Interview with Bioheart CSO, Kristin Comella including on FDA Read More »